Oxford Biomedica PLC — Board/Management Information 2014

Oct 16, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5439U

Oxford Biomedica PLC

16 October 2014

Directorate change: Additional Directorship

Oxford, UK - 16 October 2014: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Group") a leading gene and cell therapy company, announces that in accordance with Listing Rule 9.6.14R, it has been notified that Martin Diggle, a non-executive director, has been appointed as non-executive director of Proteome Sciences plc, with immediate effect.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: +44 (0)1865 783 000
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Jessica Hodgson/Matthew Neal Consilium Strategic Communications	Tel: +44 (0)20 3709 5700

Notes for editors

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Group's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDNGGGUAUUPCGAQ